Overview

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Insulin
Insulin, Globin Zinc